FindTrial
Sign In

A community study to assess the cost benefits of eradicating Helicobacter pylori in patients on long term H2 Receptor Antagonists (H2RA)

A community study to assess the cost benefits of eradicating Helicobacter pylori in patients on long term H2 Receptor Antagonists (H2RA)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN54610315
Enrollment
Unknown
Registered
2004-01-23
Start date
1993-01-06
Completion date
Unknown
Last updated
2019-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive system diseases: Peptic ulcer disease Nutritional, Metabolic, Endocrine

Interventions

1. Treatment of H. Pylori positive patients with tripotassium dicitrato bismuthate, metronidazole and oxytetracycline. 2. Active 'placebo' regime

Sponsors

NHS R&D Regional Programme Register - Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients on H2RAs

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Drug expenditure in the two practices will be compared and the number of patients restarting H2RA therapy.—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026